This may be partly explained by a broader vascular and metabolic protective effect of TCZ: decreased lipoprotein A and serum amyloid A high-density lipoprotein [34]; decreased insulin resistance through IL-17 inhibition [35]; decreased osteoclastic bone destruction [34]; and improved control of disease activity. Here, IL17A is linked to Insulin resistance.